NCT05373446View on ClinicalTrials.gov

Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study

PHASE2UnknownINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 20, 2022

Primary Completion Date

October 31, 2022

Study Completion Date

March 31, 2023

Conditions
COVID-19
Interventions
DRUG

SSD8432 300mg

SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID

DRUG

SSD8432 750mg

SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID

DRUG

SSD8432Placebo

SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID

Sponsors
All Listed Sponsors
lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY